Verastem Advances RAF/MEK/FAK Inhibitor Cancer Therapies Amid Nasdaq Growth
Verastem, a development-stage biopharma firm, targets RAF, MEK and FAK pathways to develop breakthrough cancer therapies, aiming to reshape oncology treatment.
2 minutes to read


